Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205.

G. von Wichert,T. Hoehler,C. C. Schimanski,Markus Moehler,Ralf-Dieter Hofheinz,S. Kanzler,Axel Hinke,Thomas Seufferlein,Jürgen Siebler,Andreas Hochhaus,Dirk Arnold,Michael Hallek,Ulrich Hacker

Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205.

2011

G. von Wichert
T. Hoehler
C. C. Schimanski
Markus Moehler
Ralf-Dieter Hofheinz
S. Kanzler
Axel Hinke
Thomas Seufferlein
Jürgen Siebler
Andreas Hochhaus
Dirk Arnold
Michael Hallek
Ulrich Hacker

3583 Background: Inhibition of PDGF-receptor-β-signaling using the tyrosine kinase inhibitor Ima may enhance the effects of Bev on tumor angiogenesis and improve accessibility of chemotherapy and c...

Keywords:

Capecitabine
Physical therapy
Bevacizumab
Cancer research
Colorectal cancer
Imatinib
Medicine
Internal medicine
Oncology
Oxaliplatin
phase i ii
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations